BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 22,083 Shares of Hologic, Inc. (HOLX)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lowered its position in Hologic, Inc. (NASDAQ:HOLX) by 13.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,801 shares of the medical equipment provider’s stock after selling 22,083 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned approximately 0.05% of Hologic worth $5,276,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Parnassus Investments CA bought a new stake in shares of Hologic during the 3rd quarter worth about $277,062,000. Capital World Investors bought a new stake in shares of Hologic during the 2nd quarter worth about $312,441,000. HealthCor Management L.P. bought a new stake in shares of Hologic during the 2nd quarter worth about $76,604,000. Columbus Circle Investors acquired a new position in shares of Hologic during the 2nd quarter worth about $54,511,000. Finally, Vanguard Group Inc. lifted its position in shares of Hologic by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after purchasing an additional 1,200,825 shares during the last quarter. Hedge funds and other institutional investors own 98.08% of the company’s stock.

In other news, Director Lawrence M. Levy sold 9,596 shares of the stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total value of $353,228.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Karleen Marie Oberton sold 1,023 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,833 shares of company stock valued at $1,107,270. Insiders own 0.79% of the company’s stock.

Hologic, Inc. (NASDAQ:HOLX) opened at $43.68 on Thursday. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $12,080.46, a P/E ratio of 21.69, a price-to-earnings-growth ratio of 2.12 and a beta of 0.95. Hologic, Inc. has a twelve month low of $35.76 and a twelve month high of $46.80.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, beating the consensus estimate of $0.49 by $0.01. The firm had revenue of $802.90 million during the quarter, compared to analysts’ expectations of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 EPS. equities research analysts expect that Hologic, Inc. will post 2.12 earnings per share for the current year.

Several equities analysts recently weighed in on the company. Cowen raised Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price objective for the company in a research report on Monday. Needham & Company LLC reissued a “buy” rating and set a $48.00 price objective (up previously from $46.00) on shares of Hologic in a research report on Tuesday, December 5th. Goldman Sachs Group raised Hologic from a “buy” rating to a “conviction-buy” rating and boosted their price objective for the stock from $45.00 to $50.00 in a research report on Friday, December 8th. Piper Jaffray Companies reissued a “buy” rating and set a $48.00 price objective on shares of Hologic in a research report on Thursday, November 9th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $45.00 price objective (down previously from $48.00) on shares of Hologic in a research report on Monday, October 9th. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $47.86.

COPYRIGHT VIOLATION NOTICE: “BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 22,083 Shares of Hologic, Inc. (HOLX)” was originally published by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://weekherald.com/2017/12/14/british-columbia-investment-management-corp-sells-22083-shares-of-hologic-inc-holx.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply